Cost Implications of Improving Blood Pressure Management Among U.S. Adults

Published in: HSR, Health Services Research, v. 46, no. 4, Aug. 2011, p. 1124-1157

Posted on on February 08, 2011

by Teryl K. Nuckols, Julia E. Aledort, John L. Adams, Julie Lai, Myong-Hyun Go, Joan Keesey, Elizabeth A. McGlynn

Read More

Access further information on this document at HSR

This article was published outside of RAND. The full text of the article can be found at the link above.

OBJECTIVE: To examine the cost-effectiveness of improving blood pressure management from the payer perspective. DATA SOURCE/STUDY SETTING: Medical record data for 4,500 U.S. adults with hypertension from the Community Quality Index (CQI) study (1996–2002), pharmaceutical claims from four Massachusetts health plans (2004–2006), Medicare fee schedule (2009), and published literature. Study Design. A probability tree depicted blood pressure management over 2 years. DATA COLLECTION/EXTRACTION METHODS: We determined how frequently CQI study subjects received recommended care processes and attained accepted treatment goals, estimated utilization of visits and medications associated with recommended care, assigned costs based on utilization, and then modeled how hospitalization rates, costs, and goal attainment would change if all recommended care was provided. PRINCIPAL FINDINGS: Relative to current care, improved care would cost payers U.S.$170 more per hypertensive person annually (2009 dollars). The incremental cost per person newly attaining treatment goals over 2 years would be U.S.$1,696 overall, U.S.$801 for moderate hypertension, and U.S.$850 for severe hypertension. Among people with severe hypertension, blood pressure would decline substantially but seldom reach goal; the incremental cost per person attaining a relaxed goal (≤stage 1) would be U.S.$185. CONCLUSIONS: Under the Health Care Effectiveness Data and Information Set program, which monitors the attainment of blood pressure treatment goals, payers will find it slightly more cost-effective to improve care for moderate than severe hypertension. Having a secondary, relaxed goal would substantially increase payers' incentive to improve care for severe hypertension.

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.